Skip Nav Destination
Proteasome inhibitors in Waldenström macroglobulinemia
Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)
CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism
Issue Archive
November 7 2013
Table of Contents
EDITORIAL
INSIDE BLOOD
CLINICAL TRIALS & OBSERVATIONS
Proteasome inhibitors in Waldenström macroglobulinemia
Clinical Trials & Observations
BLOOD WORK
PLENARY PAPER
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients
Stefan K. Barta,Xiaonan Xue,Dan Wang,Roni Tamari,Jeannette Y. Lee,Nicolas Mounier,Lawrence D. Kaplan,Josep-Maria Ribera,Michele Spina,Umberto Tirelli,Rudolf Weiss,Lionel Galicier,Francois Boue,Wyndham H. Wilson,Christoph Wyen,Albert Oriol,José-Tomás Navarro,Kieron Dunleavy,Richard F. Little,Lee Ratner,Olga Garcia,Mireia Morgades,Scot C. Remick,Ariela Noy,Joseph A. Sparano
BLOOD SPOTLIGHT
REVIEW SERIES
CLINICAL TRIALS AND OBSERVATIONS
Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)
Clinical Trials & Observations
Meletios A. Dimopoulos,Ramón García-Sanz,Maria Gavriatopoulou,Pierre Morel,Marie-Christine Kyrtsonis,Eurydiki Michalis,Zafiris Kartasis,Xavier Leleu,Giovanni Palladini,Alessandra Tedeschi,Dimitra Gika,Giampaolo Merlini,Efstathios Kastritis,Pieter Sonneveld
GENE THERAPY
IMMUNOBIOLOGY
Cell-intrinsic regulation of murine dendritic cell function and survival by prereceptor amplification of glucocorticoid
Annelise Soulier,Sandra M. Blois,Shivajanani Sivakumaran,Farnaz Fallah-Arani,Stephen Henderson,Barry Flutter,Elizabeth H. Rabbitt,Paul M. Stewart,Gareth G. Lavery,Clare Bennett,S. John Curnow,Ronjon Chakraverty
LYMPHOID NEOPLASIA
Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype
Gabriele Migliorini,Bettina Fiege,Fay J. Hosking,Yussanne Ma,Rajiv Kumar,Amy L. Sherborne,Miguel Inacio da Silva Filho,Jayaram Vijayakrishnan,Rolf Koehler,Hauke Thomsen,Julie A. Irving,James M. Allan,Tracy Lightfoot,Eve Roman,Sally E. Kinsey,Eamonn Sheridan,Pamela Thompson,Per Hoffmann,Markus M. Nöthen,Thomas W. Mühleisen,Lewin Eisele,Martin Zimmermann,Claus R. Bartram,Martin Schrappe,Mel Greaves,Martin Stanulla,Kari Hemminki,Richard S. Houlston
Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing
Jason A. Dubovsky,Danielle L. Chappell,Bonnie K. Harrington,Kitty Agrawal,Leslie A. Andritsos,Joseph M. Flynn,Jeffrey A. Jones,Michael E. Paulaitis,Brad Bolon,Amy J. Johnson,John C. Byrd,Natarajan Muthusamy
CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism
Brief Report
Antonella Zucchetto,Chiara Caldana,Dania Benedetti,Erika Tissino,Francesca Maria Rossi,Evelyn Hutterer,Federico Pozzo,Riccardo Bomben,Michele Dal Bo,Giovanni D’Arena,Francesco Zaja,Gabriele Pozzato,Francesco Di Raimondo,Tanja N. Hartmann,Davide Rossi,Gianluca Gaidano,Giovanni Del Poeta,Valter Gattei
MYELOID NEOPLASIA
PLATELETS AND THROMBOPOIESIS
Clot retraction is mediated by factor XIII-dependent fibrin-αIIbβ3-myosin axis in platelet sphingomyelin-rich membrane rafts
Kohji Kasahara,Mizuho Kaneda,Toshiaki Miki,Kazuko Iida,Naoko Sekino-Suzuki,Ikuo Kawashima,Hidenori Suzuki,Motoyuki Shimonaka,Morio Arai,Yoshiko Ohno-Iwashita,Soichi Kojima,Mitsuhiro Abe,Toshihide Kobayashi,Toshiro Okazaki,Masayoshi Souri,Akitada Ichinose,Naomasa Yamamoto
TRANSPLANTATION
CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT
Martin Schmidt-Hieber,Myriam Labopin,Dietrich Beelen,Liisa Volin,Gerhard Ehninger,Jürgen Finke,Gerard Socié,Rainer Schwerdtfeger,Nicolaus Kröger,Arnold Ganser,Dietger Niederwieser,Emmanuelle Polge,Igor W. Blau,Mohamad Mohty
VASCULAR BIOLOGY
CORRESPONDENCE
-
Cover Image
Cover Image
![issue cover]()
Immunofluorescence microscopy image (confocal extended focus) of a megakaryocyte cultured from Nbeal2−/− mouse bone marrow. Visible structures include a multilobed nucleus (light blue), surface membrane defined by CD41/integrin αIIb (green), and nascent proplatelet extensions defined by α-tubulin cytoskeletal strands and loops (violet). Compared to wild type, Nbeal2−/− megakaryocytes show delayed and abnormal development, including aberrant distribution of von Willebrand factor (red), some of which appears outside this cell. See the article by Kahr et al on page 3349.
- PDF Icon Front MatterFront Matter
- PDF Icon Table of ContentsTable of Contents
- PDF Icon Back MatterBack Matter
- PDF Icon AdvertisingAdvertising
- PDF Icon Editorial BoardEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
